恶性血液病化疗过程中同时抗乙肝病毒疗效的Meta分析  

The efficacy of anti-hepatitis B virus during chemotherapy for hematologic malignancies: An update Meta- analysis of randomized controlled trials

作　　者：靳鸣 宋燕燕[1] 裴梦婉 肖晖[1] 

机构地区：[1]武汉大学中南医院血液内科,湖北武汉430071

出　　处：《现代肿瘤医学》2016年第22期3606-3611,共6页Journal of Modern Oncology

摘　　要：目的:运用Meta分析评价恶性血液病化疗过程中预防性应用抗乙肝病毒药物的疗效。方法:计算机检索Cochrane Central Register of Controlled Trials、MEDLINE、EMBase、中国知网(CNKI)、万方数据库(Wanfang Data)、维普数据库(VIP)、中国生物医学文献数据库(CBM)中关于携带乙肝病毒的恶性血液病患者化疗同时抗病毒的随机对照实验,同时追索纳入文献的参考文献。检索时限均为从建库至2015年3月。统计学分析采用Rev Man5.2软件。结果:现有研究显示,携带乙肝病毒的恶性血液病患者化疗同时应用抗病毒药物可以降低患者乙肝病毒激活率,降低化疗延迟率和肝炎相关病死率,减少肝功能损害的情况,从整体上改善患者化疗后不良临床反应,既可以改善患者的生存质量,又可以延长生存时间。结论:建议对HBV携带的恶性血液病患者化疗前应预防应用抗病毒药物。Objective： Evaluating the efficacy of anti- hepatitis B virus by Meta- analysis in the use of chemotherapy for hematologic malignancies. Methods： We searched related papers about randomized controlled trials ofapplying chemotherapy and antiviral treatment on patients with hematologic malignancies and hepatitis B virus（ HBV）in Cochrane Central Register of Controlled Trials,MEDLINE,EMBase,CNKI,Wanfang Data,VIP database,CBM. Retrieved time limits are from the time of building a database to December 2015. Statistical analysis was performed by RevM an5. 2 software. Results： Existing studies showed that applying chemotherapy and antiviral treatment simultaneously on patients with hematologic malignancies and HBV can reduce activation rate of HBV,chemotherapy latency rate,hepatitis- related mortality rate,and the rate of liver dysfunction,have overall improvement of adverse clinical response in patients with chemotherapy. Conclusion： The treatment can improve the life quality of patients,prolong the survival time. therefore,it is suggested that we should apply antiviral drugs on patients with hematologic malignancies and HBV preventively before chemotherapy.

关 键 词：恶性血液病 乙肝病毒 化疗 抗病毒 

分 类 号：R735.7[医药卫生—肿瘤]